Treatment of Hirudin Overdosage in a Patient with Chronic Renal Failure

Thromb Haemost 1999; 81(02): 323-324
DOI: 10.1055/s-0037-1614470

Letters to the Editor

Schattauer GmbH

R. M. Bauersachs

,

E. Lindhoff-Last

,

A. M. Ehrly

,

Ch. Betz

¹Division of Nephrology, IV. Medical Department, Centre of Internal Medicine, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany

,

H. Geiger

¹Division of Nephrology, IV. Medical Department, Centre of Internal Medicine, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany

,

I. A. Hauser

¹Division of Nephrology, IV. Medical Department, Centre of Internal Medicine, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany

References
1 Topol EJ, Fuster V, Harrinton RA, Califf RM, Kleiman NS, Kereiakes DJ, Cohen M, Chapekis A, Gold HK, Tannenbaum MA. et al. Recombinant Hirudin for unstable Angina Pectoris. A multicenter, randomized angiographic Trial. Circulation 1994; 89: 1557-66.
2 Anonymous. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Circulation 1997; 96: 769-77.
3 Eriksson I B, Ekman S, Kälebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996; 347: 635-9.
4 Nowak G, Bucha A. Quantitative determination of hirudin in blood and body fluids. Sem Thromb Hemost 1996; 22: 197-202.